drugset
drugset / Trial / NCT04084197

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HIP1801 in Healthy Male Subjects.

NCT04084197 ↗

Phase 1 Completed 61 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

An open-label, randomized, single-dose crossover study to evaluate the pharmacokinetics, safety and tolerability of HIP1801 in healthy male subjects.

Timeline

Start
2018-12-19
Primary completion
2018-12-31
Completion
2019-01-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Tamsulosin Other / unclassified 0.4 mg —

Indications

No indication recorded.